Phase 2 N=11 Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures.
Distal Radius Fractures
Primary: Safety: Serious Treatment-emergent Adverse Events (TEAEs) and NVDX3-related TEAEs — 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis
Endometriosis · Ovarian Hyperstimulation
Primary: Average Delta in Endometriosis Pain Score Pre and Post Stimulation With and Without Use Of Letrozole — -2.5; -2.7 Change in score on a scale
Phase 2 N=211 Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Neoplasm Metastasis · Advanced Tumors · Metastatic Solid Tumors
Primary: [Module C] Objective Response (OR) — 14.3; 23.3; 0.0; 3.3 percentage of participants
Phase 2 N=43 Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Hematological Malignancy · Multiple Myeloma
Primary: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. — 17 Participants
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
Phase 2 N=68 Symptom Clusters in Children With Exacerbation-prone Asthma
Asthma in Children
Primary: Change in Asthma Control Questionnaire (ACQ) Score — 0.52 score on a scale
Phase 2 N=80 Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)
Respiratory Syncytial Virus Infection
Primary: Percentage of Placebo Receiving Pediatric Participants With Vaccine Virus Detected in Nasal Swabs After the First Vaccination — 0; 0; 0; 0 percentage of participants
Phase 2 N=161 Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
HIV-1 Infection
Primary: Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind — 75.0; 75.6; 80.0; 67.5…
Phase 2 N=41 Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Cardiomyopathy · Cardiomyopathy, Dilated
Primary: Incidence of Treatment-Emergent Adverse Events — 14; 9; 10 Participants
Phase 2 N=125 Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia
Bronchopulmonary Dysplasia of Newborn
Primary: Safety Based Upon Number of Participants With Hypotension — 1; 0; 0; 0 Participants
Phase 2 N=31 Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
Prostatic Neoplasms
Primary: Percentage of Patients With Castrate Level of Serum Testosterone — 25 Participants
Phase 2 N=121 Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis
Primary: Number of Participants With Treatment Emergent Adverse Events — 21; 10; 16; 15 Participants
Phase 2 N=15 Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis · IPF
Primary: Absolute Change From Baseline in Forced Vital Capacity for 26 Weeks — -0.177; -0.025 Liters
Phase 2 N=16 Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Solid Tumor, Adult
Primary: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). — 11; 3 Participants
Phase 2 N=10 Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Advanced Pancreatic Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v8
Primary: Assessment of Tumor Response to Combination of Paricalcitol and Hydroxychloroquine With Common Front-line Therapy. — 43 percentage of participants